AGLE News and Press, Aeglea BioTherapeutics Inc. From 12/06/21

Shares of Aeglea BioTherapeutics (NASDAQ: AGLE) , a clinical-stage biopharmaceutical company , are falling today in response to mixed clinical-trial data. Investors nervous about the future of the company's lead candidate pushed the stock 36.6% lower as of 11:53 a.m. ET on Monda...

Gainers: Del Taco Restaurants (NASDAQ:TACO) +66%. Insignia Systems (NASDAQ:ISIG) +64%. Adicet Bio (NASDAQ:ACET) +37%. Cloopen Group (NYSE:RAAS) +24%. eFFECTOR Therapeutics (NASDAQ:EFTR) +20%. Recruiter (NASDAQ:RCRT) +21%. Edgewise Therapeutics (NASDAQ:EWTX) +21%. Liberty TripAdvisor (NASDAQ:L...

Alset EHome International (NASDAQ:AEI) -43% prices $30M stock offering TuanChe (NASDAQ:TC) -18%. Lucid Group (NASDAQ:LCID) -15%. Hut 8 Mining (NASDAQ:HUT) -15%. Bitfarms (NASDAQ:BITF) -15%. Aeglea BioTherapeutics (NASDAQ:AGLE) -14% says pivotal trial for pegzilarginase in ...

Aeglea BioTherapeutics (NASDAQ:AGLE) announced that its Phase 3 pivotal trial for pegzilarginase in Arginase 1 Deficiency met the primary endpoint. However, a key measure designed to assess the patient's mobility have not achieved statistical significance. Aeglea (AGLE) have lost ~18.0%&...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! We’re starting off the week with a look at the biggest pre-market stock movers for Monday! Source: Eric Urquhart/Shutterstock.com News moving stocks this morning include falling crypto p...

Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency 80% plasma arginine reduction (primary endpoint; p < 0.0001) accompanied by a positive trend in GMFM-E, a key clinical assessment of pati...

Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency Event Scheduled for 8:00 a.m. ET Monday, December 6, 2021 PR Newswire AUSTIN, Texas , Dec. 5, 2021 /PRNewswire/ -- Aeglea...

Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors PR Newswire AUSTIN, Texas , Nov. 16, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therape...

Aeglea BioTherapeutics (NASDAQ:AGLE): Q3 GAAP EPS of -$0.31 misses by $0.01. Revenue of $1.39M Press Release For further details see: Aeglea BioTherapeutics EPS misses by $0.01

Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights PEACE baseline data at upcoming medical meeting underscore disease severity and significant limitations of current standard of care in controlling plasma arginine levels Topline safe...